- The FDA has granted breakthrough device designation to Abiomed Inc's ABMD Impella ECP expandable percutaneous heart pump.
- Abiomed designed the Impella ECP heart pump to be compatible with small-bore access and closure techniques. It measures 3 mm in diameter when inserted and removed from the body.
- It expands in the heart to support its pumping function and provides a flow greater than 3.5 L/min.
- Abiomed's breakthrough device designation follows the FDA's premarket approval of its Impella RP right heart pump in June.
- Related content: Benzinga's Full FDA Calendar.
- Price Action: ABMD shares are up 1.34% at $332.97 during the market session on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
